Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression

BACKGROUND: Substantial residual cardiovascular risk remains after optimal LDL lowering in patients of established coronary artery disease. A number of therapeutic agents that raise HDL-C have been tested in clinical trials to cover this risk. However, the results of clinical trials are conflicting....

Descripción completa

Detalles Bibliográficos
Autores principales: Kaur, Navjot, Pandey, Avaneesh, Negi, Harish, Shafiq, Nusrat, Reddy, Srinivas, Kaur, Harpreet, Chadha, Neelima, Malhotra, Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984171/
https://www.ncbi.nlm.nih.gov/pubmed/24728455
http://dx.doi.org/10.1371/journal.pone.0094585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984171/
https://www.ncbi.nlm.nih.gov/pubmed/24728455
http://dx.doi.org/10.1371/journal.pone.0094585

Ejemplares similares